Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Parallel-Group, Phase I Study to Compare the Pharmacokinetics of NKTR-118 Following a Single Oral Dose in Subjects With Renal Impairment and Subjects With Normal Renal Function

NCT01372826 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01372826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01372826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Parallel-Group, Phase I Study to Compare the Pharmacokinetics of NKTR-118 Following a Single Oral Dose in Subjects With Renal Impairment and Subjects With Normal Renal Function
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2011
Completion date
November 30, 2011
Enrollment
32 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

renal impairment